Smoking, T4 tumors up distant mets in HPV+ oropharyngeal CA

Smoking, T4 tumors up distant mets in HPV+ oropharyngeal CA
(HealthDay)—For patients with human papillomavirus (HPV)-positive oropharyngeal cancer, active smokers and those with T4 tumors have increased rates of distant metastases, according to a study published online Feb. 11 in Head & Neck.

Michael A. Weller, M.D., from the Cleveland Clinic, and colleagues examined predictors of distant metastases in with stage III to IVb HPV-positive oropharyngeal cancer treated with cisplatin-based chemoradiotherapy (CRT) or cetuximab-based bioradiotherapy (bio-RT).

The researchers found that the rates of distant metastases were increased for active smokers compared with never/former smokers (22 versus 5 percent), for those with T4 versus T1 to T3 tumors (15 versus 6 percent), and with use of cetuximab-based bio-RT versus CRT (23 versus 5 percent). On multivariate analyses, all factors remained significant.

"Patients with HPV-positive oropharyngeal with T4 tumors and/or are active smokers have substantial rates of distant metastases (>20 percent), and trials investigating intensified systemic therapies may be considered in this population," the authors write. "Retrospective observations from this patient cohort demonstrate an increased rate of distant metastases in patients treated with cetuximab when compared with patients with cisplatin, but until further data are available, this should be considered hypothesis generating."


Explore further

Researchers urge radiotherapy for all patients with bone mets

More information: Full Text (subscription or payment may be required)

Copyright © 2017 HealthDay. All rights reserved.

Citation: Smoking, T4 tumors up distant mets in HPV+ oropharyngeal CA (2017, February 15) retrieved 19 May 2019 from https://medicalxpress.com/news/2017-02-t4-tumors-distant-mets-hpv.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
0 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more